AstraZeneca – Call For Grants (CGA OIC 1402)
Therapeutic Area: Neurology/Pain
Disease State: Opioid-Induced Constipation (OIC)
Call for Grants Application (CGA) Title: “CGA OIC 1402– Program Title…”
•
Your title must begin with CGA ID number.
•
Refer to Grant Submission Instructions for further information on submitting
your formal grant application.
Submission Deadline:
Proposal:
Educational Audience:
Program Format:
Program Cost:
November 21, 2014; 12 noon EST
Support for an accredited educational initiative
focusing on the pharmacological treatment of
patients who are suffering with
opioid-induced constipation
Pharmacists, specifically:
 Community-based
 Hospital-based
 Long-term care
 Consultant
 Managed care
 Pharmacy directors
Seeking an innovative, multi-media initiative that may
include:
 Live satellite symposia
 Web-based programs
 Print
Applications are encouraged to:
 include pharmacist-delivered patient
education
 include Level 4/5 outcomes
 be multi-supported
≤ $425,000.00
AstraZeneca is interested in providing grant support for independent education
activities in the area of opioid-induced constipation (OIC) that addresses the
educational needs and practice gaps of pharmacists caring for patients suffering
from chronic pain and provides evidence-based solutions geared at meeting the
unmet medical needs of this patient population.
Needs Assessment: For Opioid-Induced Constipation
Approximately 100 million American adults suffer from chronic pain, a condition that
costs our nation up to $635 billion each year in medical treatment and lost
productivity (Institute of Medicine 2011). Opioid analgesics are widely used to
manage moderate-to-severe pain in patients for whom alternative treatments are
ineffective or not tolerated. These medications are associated with a broad range of
adverse effects.
Opioid-induced constipation (OIC) is one of the most common side effects
associated with chronic opioid therapy (Benyamin et al 2008). OIC can interfere with
pain management, impair daily activities and quality-of- life, decrease work
productivity and may potentially lead to increased health care utilization (Bell et al
2009a,b; Coyne et al 2014).
OIC is often under-recognized and undertreated by physicians for a number of
reasons (Panchal et al 2007; Brock et al 2012; McKay et al 2014). Since pharmacists
work closely with the entire healthcare team to optimize medication use according to
evidence-based guidelines and provide medication therapy management
recommendations, pharmacists are an excellent resource for patients who are
suffering from OIC (American Pharmacists Association and National Association of
Chain Drug Stores Foundation 2008; Rausch and Jansen 2012).
Given this, pharmacists may benefit from education on:



Pathophysiology of OIC
Assessment, diagnosis, and management of OIC
Pharmacological treatment options for OIC
References:
American Pharmacists Association and National Association of Chain Drug Stores
Foundation (2008). Medication Therapy Management in Pharmacy Practice: Core
Elements of an MTM Service Model. Version 2.
http://www.pharmacist.com/sites/default/files/files/core_elements_of_an_mtm_practi
ce.pdf . Published March 2008. Accessed on July 25, 2014.
Bell TJ et al. The prevalence, severity, and impact of opioid-induced bowel
dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med
2009a;10:35-42.
Bell TJ et al. Opioid-induced constipation negatively impacts pain management,
productivity, and health-related quality-of-life: Findings from the National Health and
Wellness Survey. J Opioid Management 2009b;5(3)3:137-144.
Benyamin et al. Opioid complications and side effects. Pain Physician 2008;
11;S105-S120.
Brock C et al. Opioid-induced bowel dysfunction: pathophysiology and management.
Drugs 2012;72(14):1847-1865.
Coyne KS et al. Opioid-induced constipation in patients with chronic noncancer pain
in the USA, Canada, Germany, and the UK: descriptive analysis of baseline
patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes
Res 2014;6:269-281.
Institute of Medicine (2011). Relieving Pain in America: A Blueprint for Transforming
Prevention, Care, Education, and Research.
http://www.nap.edu/catelog.php?record_id=13172. Published June 2011. Accessed
on July 23, 2014.
McKay SL, Fravel M, Scanlon C. Management of constipation. Guideline summary
NGC-7535. http://www.guideline.gov/popups/printView.aspx?id=15434. Published
October 2009. Accessed June 11, 2014.
Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction:
prevalence, pathophysiology and burden. Int J Clin Pract 2007;61(7):1181-1187.
Rausch T and Jansen T. Gastrointestinal side effects of opioid analgesics. US
Pharm 2012;37(12):36-39.
Program Requirements:
The Program must be accredited and fully compliant with the criteria and/or
standards of commercial support for ACCME, AAFP, AOA, ACPE, ANCC, AANP, or
NCCPA. Furthermore, the program will be educational and non-promotional in
nature and will be planned, designed and implemented in accordance with the U.S.
Food and Drug Administration’s Guidance on Industry-Supported Scientific and
Educational Activities ("Policy Statement").
The Policy Statement and the ACCME Standards require, among other things, that
(i) Institution conduct the Program independently and without control or influence by
AstraZeneca over the Program's planning, content (including the selection of
speakers or moderators), or execution; (ii) the Program be free of commercial bias
for or against any product; (iii) Institution make meaningful disclosure of AstraZeneca
support of the Program and any prior relationship between Institution and
AstraZeneca, and the relationship, if any, between AstraZeneca and the speakers
selected by Institution; and (iv) AstraZeneca not engage in, and Institution not permit
any other sponsor to engage in, promotional activities in or near the Program room
or advertise its products in any materials disseminated as part of the Program.
In addition, Institution is required by the Policy Statement and the ACCME Standards
to ensure that any product discussions at the Program be accurate, objective,
balanced and scientifically rigorous. This includes a balanced discussion of each
product and of treatment alternatives, that limitations on data be disclosed, that
unapproved uses be identified as such, and that for live presentations there be
opportunities for questioning or debate.
REMINDER - Submission Instructions:
Call for Grants Application Title: “CGA OIC 1402– Program Title…”
Submission Instructions:
• Your title must begin with Call for Grants Application (CGA) ID number.
• Refer to Grant Submission Instructions for further information on
submitting your formal grant application.